Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma

This study is ongoing, but not recruiting participants.

Study NCT00410462 Information provided by National Cancer Institute (NCI)

First Received: December 11, 2006 Last Updated: July 10, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given

Publications:

Gelderblom H, Blay J, Seddon BM, et al.: Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An EORTC Soft Tissue and Bone Sarcoma Group randomized phase II study. [Abstract] J Clin Oncol 28 (Suppl 15) A-10037, 2010.